Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

relate these promising in vitro data."

Steven Porter, CEO of Ceragenix stated: "The publication of peer-reviewed research on our Ceragenin(TM) compounds is an important milestone for our Company and a key element in obtaining recognition for our technology in the scientific community. We look forward to future publications from our ongoing preclinical research activities on the safety and efficacy work that is now being conducted in vivo."

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram(TM) and NeoCeram(TM). For additional information on Ceragenix, please visit www.ceragenix.com.

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of the company to raise sufficient capital to finance its planned activities; the ability of the company to satisfy its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration; suc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... 1, 2014  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for ... expansion of its European operations with the formation of a ... as General Manager, Germany.  Mr. Schaber will join former Kyphon ... Europe , Middle East ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... October 1, 2014 Patients with increased inflammation, ... a greatly increased risk of depression. For example, ... chronic hepatitis C virus infection causes depression in ... acids, more commonly known as fish oil, have ... the risk of heart disease and reducing triglyceride ...
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... 01, 2014 Between 23 million and ... U.S., according to figures from the National Institutes of ... (AARDA), and many of them have something else in ... undiagnosed celiac disease. Gluten Free Therapeutics, makers of ... undiagnosed celiac disease by publishing a series of blog ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... Attorneys from Dallas, Rasansky Law Firm are ... of the mother of a 2-year-old girl who choked to death ... lawsuit includes claims that the day care,s owners quickly sold the ... from showing up on a state licensing database. , According to ...
... WAYNE, Pa., Nov. 5 Qualsec,s (OTC Bulletin ... received an order from DMC Athletics & ... business will offer products of QLSZ,s wholly-owned subsidiary, ... providing dietary support to their various wellness programs. ...
... DUE TO AN EMBARGO BREAK , From their very first days, ... speak, reveals a new study published online on November 5th in ... that infants begin picking up elements of what will be their ... babble or coo. "The dramatic finding of this study is ...
... left demanding jobs report the most improvement, study finds, , ... doing once retired seems to make a good night,s ... French workers who had retired found that the odds of ... 26 percent lower than in the seven years before they ...
... Research Institute calls for further investigations into the use of ... Nov. 5 Two studies published by the Southwest College ... Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid ... lead poisoning, and used off-label in these studies for treating ...
... ... for the ClearCanvas customer base of more than 5,000 radiology software users worldwide. ... Toronto, Ontario (PRWEB) ... premier support provider for ClearCanvas, Inc. open source RIS/PACS products. Oso Healthcare ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:Qualsec's Wholly-Owned Subsidiary Receives Order From New Jersey-Based DMC Athletics and Rehabilitation 2Health News:Babies' language learning starts from the womb 2Health News:Without Job Stress, Retirees Sleep Better 2Health News:Chelation Therapy Drug Found Safe and Beneficial for Children With Autism 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 3Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 4
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
Magnetic Farnsworth D15 kit Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
... the Farnsworth-Munsell 100 Hue Test. It is intended ... study of a color vision defect. It provides ... difficulty in distinguishing color differences in certain tasks. ... reference caps with Munsell notations, plus a neutral ...
Spanish HRR/Amsler combination with Spanish and English directions for both HRR and amsler tests plus occluding glasses....
Medicine Products: